<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02051842</url>
  </required_header>
  <id_info>
    <org_study_id>GAS-1081-13/14-1</org_study_id>
    <nct_id>NCT02051842</nct_id>
  </id_info>
  <brief_title>Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis</brief_title>
  <official_title>Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxidative stress is produced by imbalance between reactive oxygen species and antioxidant
      systems. This state is frequently associated with chronic diseases like obesity, insulin
      resistance, metabolic syndrome and hepatic steatosis. In the liver, the oxidative stress may
      trigger the progression of fatty liver disease, from triglyceride accumulation to
      inflammation, cirrhosis and hepatocellular carcinoma. Thus, the attenuation of oxidative
      stress, could be an important therapeutic target to lessen the severity of the disease. Until
      now, there is not a medical treatment to cure non-alcoholic fatty liver disease, but
      therapies aimed at reducing oxidative stress have been proposed. Metadoxine, an ionic complex
      of pyridoxine-pyrrolidone molecule, acts as a synthetic antioxidant, forming traps that can
      reduce free radicals; likewise, metadoxine has a proven capacity to reduce fat liver in
      alcoholic hepatitis. Finally, in fact that alcoholic and non-alcoholic liver diseases share
      molecular mechanisms in the generation of oxidative stress, the investigators propose
      metadoxine as a posssible modifier of the oxidative stress in non-alcoholic liver disease,
      prediabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxidative stress</measure>
    <time_frame>Baseline</time_frame>
    <description>Malondialdehyde levels</description>
  </primary_outcome>
  <other_outcome>
    <measure>Oxidative stress</measure>
    <time_frame>3 month follow-up</time_frame>
    <description>Malondialdehyde levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Oxidative stress</measure>
    <time_frame>6 months follow-up</time_frame>
    <description>Malondialdehyde levels</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>NAFLD</condition>
  <condition>Pre-diabetes</condition>
  <arm_group>
    <arm_group_label>Metadoxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metadoxine 500 mg tablets by mouth every 12 hours for 6 months and metformin 500 mg tablets by mouth every 8 hours for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet (for Metadoxine) by mouth every 12 hours for 6 months and metformin 500 mg tablets by mouth every 8 hours for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metadoxine</intervention_name>
    <arm_group_label>Metadoxine</arm_group_label>
    <arm_group_label>Placebo tablet</arm_group_label>
    <other_name>Metadoxil</other_name>
    <other_name>Abrixone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female

          -  18 to 65 years old

          -  Ultrasonographic diagnosis of NAFLD

          -  Prediabetes diagnosis

        Exclusion Criteria:

          -  Alcoholism

          -  Hepatitis C or B Virus Infection

          -  Pregnancy

          -  Autoimmune hepatitis

          -  Metformin or metadoxine allergy

          -  Parenteral nutrition in the last month

          -  Weigh loss greater than 10% in the last month

          -  Taking vitamin supplements in the last month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aldo Torre, MD MSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aldo Torre, M.D., M.Sc.</last_name>
    <phone>54870900</phone>
    <phone_ext>2711</phone_ext>
    <email>detoal@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Médicas y Nutrición &quot;Salvador Zubirán&quot;</name>
      <address>
        <city>Mexico City</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aldo Torre, M.D, M.Sc.</last_name>
      <phone>54870900</phone>
      <phone_ext>2711</phone_ext>
      <email>detoal@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Aldo Torre, MD MSci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2014</study_first_submitted>
  <study_first_submitted_qc>January 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2014</study_first_posted>
  <last_update_submitted>June 7, 2016</last_update_submitted>
  <last_update_submitted_qc>June 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>ALDO TORRE DELGADILLO</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>NAFLD</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>malondialdehyde</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metadoxine</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

